Pyxis Oncology Reports Expanded Losses and Milestones for MICVO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Source: NASDAQ.COM
- Financial Results: Pyxis Oncology reported a widened net loss of $79.6 million for FY2025, translating to a loss of $1.28 per share, which is an increase from a loss of $77.3 million or $1.32 per share last year, indicating ongoing financial challenges for the company.
- Revenue Decline: The company's revenue decreased from $16.1 million to $13.9 million year-over-year, reflecting weakened market competitiveness that could impact future funding capabilities and investor confidence.
- Clinical Progress: Positive preliminary data for MICVO in recurrent/metastatic head and neck squamous cell carcinoma has been announced, with updated combination data expected in the second half of 2026, showcasing the company's ongoing commitment to research and potential market opportunities.
- Cash Position: As of December 31, 2025, Pyxis had $68.3 million in cash, expected to fund operations into Q4 2026, indicating relative short-term liquidity stability, though long-term prospects remain a concern.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PYXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PYXS
Wall Street analysts forecast PYXS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.070
Low
5.00
Averages
6.90
High
9.00
Current: 3.070
Low
5.00
Averages
6.90
High
9.00
About PYXS
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gas Utilities Stocks Show Strong Performance
- Overall Uptrend: Gas utilities stocks rose approximately 1.4% as a group, indicating increased market confidence in the sector, which may reflect optimistic investor expectations for future demand.
- ONE Gas Leads: ONE Gas shares increased by about 3.5%, making it the strongest performer of the day, suggesting its competitive position in the market and positive investor sentiment.
- Spire's Recovery: Spire's stock rose approximately 3.3%, demonstrating the company's resilience in the market, potentially linked to its recent business performance or market strategies.
- Sector Leaders: Drug and gas utilities stocks stood out on Tuesday, showcasing relative strength in the current economic environment, which may attract more investor attention.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator rose by 10.98 points to 29,785.73, indicating positive investor sentiment that may drive active buying at the market open.
- Active Stocks: VisionWave Holdings, Inc. (VWAV) increased by $0.50 to $5.12 with a trading volume of 8,563,784 shares, suggesting optimistic market expectations for its future performance.
- Recommendation Ratings: Redwire Corporation (RDW) gained $0.79 to $12.48 with 3,557,130 shares traded, and Zacks reports its current mean recommendation is in the 'buy range', reflecting analysts' confidence in its growth potential.
- ETF Dynamics: ProShares UltraPro QQQ (TQQQ) rose by $0.1387 to $77.33, representing a 107.2% increase from its 52-week low, showcasing strong investor interest in tech stocks.
See More
Pyxis Oncology Secures $50 Million Financing to Extend Cash Runway
- Financing Amount: Pyxis Oncology announced a private placement financing of approximately $50 million, expected to extend the company's cash runway into the second quarter of 2027, thereby supporting funding for subsequent clinical trials.
- Clinical Data Updates: The company anticipates releasing updated monotherapy data in Fall 2026 and combination data with pembrolizumab in Q4 2026, aiming to provide more effective treatment options for head and neck cancer patients.
- Investor Support: This financing was led by BVF Partners L.P. with participation from GordonMD Global Investments, RTW Investments, and Coastlands Capital, reflecting investor confidence in the MICVO program and further strengthening the company's financial stability.
- Equity Issuance Details: Pyxis Oncology will sell 19,600,153 shares of common stock at $2.551 per share, along with an equal number of warrants, with the financing expected to close around July 2, 2026, facilitating key advancements in clinical trials.
See More
Pyxis Oncology Q1 Earnings Miss Expectations
- Earnings Performance: Pyxis Oncology reported a Q1 GAAP EPS of -$0.37, missing the expected -$0.36, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of March 31, 2026, the company had $42.5 million in cash, cash equivalents, and short-term investments, suggesting a reasonable liquidity position, but future funding needs remain a concern.
- Operational Funding Assurance: The company believes its current cash and short-term investments will be sufficient to fund operations into Q4 2026, reflecting management's optimistic outlook for the upcoming months despite profitability pressures.
- Market Reaction Outlook: Given the earnings miss, investors may adopt a cautious stance regarding the company's future growth potential, potentially leading to short-term stock price volatility.
See More
Pyxis Oncology to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Pyxis Oncology will participate in the RBC Capital Markets Global Healthcare Conference in New York on May 19, 2026, with a fireside chat at 2:35 p.m., aiming to attract investor interest in its innovative therapies for difficult-to-treat cancers.
- Virtual Forum Participation: The company will also engage in the Stifel Virtual Oncology Forum on May 20, 2026, at 3:30 p.m., enhancing its visibility among investors and showcasing its treatment options for challenging cancer cases.
- Clinical Research Progress: Pyxis Oncology's lead candidate, MICVO, is currently undergoing a Phase 1 clinical study for recurrent and metastatic head and neck squamous cell carcinoma, aiming to improve treatment outcomes through a three-pronged mechanism, highlighting the company's potential in cancer therapy.
- FDA Fast Track Designation: MICVO has received Fast Track Designation from the U.S. FDA for adult patients with recurrent and metastatic head and neck squamous cell carcinoma who have progressed after platinum-based chemotherapy and KEYTRUDA®, underscoring the strategic significance and market opportunities for the company in cancer treatment.
See More
Pyxis Oncology's maMICVO Shows Anti-Tumor Activity in HNSCC Model
- Monotherapy Efficacy: In a syngeneic preclinical model of HNSCC, maMICVO monotherapy demonstrated dose-dependent tumor growth inhibition, with 6 mg/kg achieving the strongest effect, indicating its potential in cancer treatment.
- Immune Environment Modulation: Treatment with maMICVO significantly altered the tumor immune environment by reducing the abundance of immune-suppressive regulatory T cells and increasing the CD8 T cell-to-Treg ratio, enhancing responsiveness to anti-PD-1 therapy and creating a more favorable setting for immunotherapy.
- Synergistic Combination Therapy: The combination of maMICVO and anti-mouse PD-1 exhibited greater anti-tumor activity than either treatment alone, highlighting the effectiveness of its three-pronged mechanism of action and offering new therapeutic options for immunotherapy-refractory tumors.
- Clinical Development Outlook: These preclinical findings support the ongoing clinical development of MICVO as both a monotherapy and in combination with pembrolizumab, with further updates expected in the second half of 2026 regarding 1L/2L+ R/M HNSCC patients, advancing its clinical application.
See More
Gas Utilities Stocks Show Strong Performance
- Overall Uptrend: Gas utilities stocks rose approximately 1.4% as a group, indicating increased market confidence in the sector, which may reflect optimistic investor expectations for future demand.
- ONE Gas Leads: ONE Gas shares increased by about 3.5%, making it the strongest performer of the day, suggesting its competitive position in the market and positive investor sentiment.
- Spire's Recovery: Spire's stock rose approximately 3.3%, demonstrating the company's resilience in the market, potentially linked to its recent business performance or market strategies.
- Sector Leaders: Drug and gas utilities stocks stood out on Tuesday, showcasing relative strength in the current economic environment, which may attract more investor attention.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator rose by 10.98 points to 29,785.73, indicating positive investor sentiment that may drive active buying at the market open.
- Active Stocks: VisionWave Holdings, Inc. (VWAV) increased by $0.50 to $5.12 with a trading volume of 8,563,784 shares, suggesting optimistic market expectations for its future performance.
- Recommendation Ratings: Redwire Corporation (RDW) gained $0.79 to $12.48 with 3,557,130 shares traded, and Zacks reports its current mean recommendation is in the 'buy range', reflecting analysts' confidence in its growth potential.
- ETF Dynamics: ProShares UltraPro QQQ (TQQQ) rose by $0.1387 to $77.33, representing a 107.2% increase from its 52-week low, showcasing strong investor interest in tech stocks.
See More
Pyxis Oncology Secures $50 Million Financing to Extend Cash Runway
- Financing Amount: Pyxis Oncology announced a private placement financing of approximately $50 million, expected to extend the company's cash runway into the second quarter of 2027, thereby supporting funding for subsequent clinical trials.
- Clinical Data Updates: The company anticipates releasing updated monotherapy data in Fall 2026 and combination data with pembrolizumab in Q4 2026, aiming to provide more effective treatment options for head and neck cancer patients.
- Investor Support: This financing was led by BVF Partners L.P. with participation from GordonMD Global Investments, RTW Investments, and Coastlands Capital, reflecting investor confidence in the MICVO program and further strengthening the company's financial stability.
- Equity Issuance Details: Pyxis Oncology will sell 19,600,153 shares of common stock at $2.551 per share, along with an equal number of warrants, with the financing expected to close around July 2, 2026, facilitating key advancements in clinical trials.
See More
Pyxis Oncology Q1 Earnings Miss Expectations
- Earnings Performance: Pyxis Oncology reported a Q1 GAAP EPS of -$0.37, missing the expected -$0.36, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of March 31, 2026, the company had $42.5 million in cash, cash equivalents, and short-term investments, suggesting a reasonable liquidity position, but future funding needs remain a concern.
- Operational Funding Assurance: The company believes its current cash and short-term investments will be sufficient to fund operations into Q4 2026, reflecting management's optimistic outlook for the upcoming months despite profitability pressures.
- Market Reaction Outlook: Given the earnings miss, investors may adopt a cautious stance regarding the company's future growth potential, potentially leading to short-term stock price volatility.
See More
Pyxis Oncology to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Pyxis Oncology will participate in the RBC Capital Markets Global Healthcare Conference in New York on May 19, 2026, with a fireside chat at 2:35 p.m., aiming to attract investor interest in its innovative therapies for difficult-to-treat cancers.
- Virtual Forum Participation: The company will also engage in the Stifel Virtual Oncology Forum on May 20, 2026, at 3:30 p.m., enhancing its visibility among investors and showcasing its treatment options for challenging cancer cases.
- Clinical Research Progress: Pyxis Oncology's lead candidate, MICVO, is currently undergoing a Phase 1 clinical study for recurrent and metastatic head and neck squamous cell carcinoma, aiming to improve treatment outcomes through a three-pronged mechanism, highlighting the company's potential in cancer therapy.
- FDA Fast Track Designation: MICVO has received Fast Track Designation from the U.S. FDA for adult patients with recurrent and metastatic head and neck squamous cell carcinoma who have progressed after platinum-based chemotherapy and KEYTRUDA®, underscoring the strategic significance and market opportunities for the company in cancer treatment.
See More
Pyxis Oncology's maMICVO Shows Anti-Tumor Activity in HNSCC Model
- Monotherapy Efficacy: In a syngeneic preclinical model of HNSCC, maMICVO monotherapy demonstrated dose-dependent tumor growth inhibition, with 6 mg/kg achieving the strongest effect, indicating its potential in cancer treatment.
- Immune Environment Modulation: Treatment with maMICVO significantly altered the tumor immune environment by reducing the abundance of immune-suppressive regulatory T cells and increasing the CD8 T cell-to-Treg ratio, enhancing responsiveness to anti-PD-1 therapy and creating a more favorable setting for immunotherapy.
- Synergistic Combination Therapy: The combination of maMICVO and anti-mouse PD-1 exhibited greater anti-tumor activity than either treatment alone, highlighting the effectiveness of its three-pronged mechanism of action and offering new therapeutic options for immunotherapy-refractory tumors.
- Clinical Development Outlook: These preclinical findings support the ongoing clinical development of MICVO as both a monotherapy and in combination with pembrolizumab, with further updates expected in the second half of 2026 regarding 1L/2L+ R/M HNSCC patients, advancing its clinical application.
See More
